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Abstract
 
Human immunodeficiency virus (HIV)-specific CD8
 
  
 
T cells persist in high frequencies in
HIV-infected patients despite impaired CD4
 
  
 
T helper response to the virus, but, unlike other
differentiated effector cytotoxic T lymphocytes, most continue to express the tumor necrosis
factor receptor family member CD27. Because the ligand for CD27 (CD70) is also overex-
pressed in HIV-infected hosts, we examined the nature of expression and potential functional
consequences of CD27 expression on HIV-specific CD8
 
  
 
T cells. Analysis of CD27
 
  
 
and
CD27
 
  
 
T cells derived from the same HIV-specific clone revealed that retention of CD27 did
not interfere with acquisition of effector functions, and that after T cell receptor stimulation,
CD27
 
  
 
cells that concurrently were triggered via CD27 exhibited more resistance to apoptosis,
interleukin 2 production, and proliferation than CD27
 
  
 
T cells. After transfer back into an
HIV-infected patient, autologous HIV-specific CD27
 
  
 
T cells rapidly disappeared, but CD27
 
 
 
T cells derived from the same clone persisted at high frequency. Our findings suggest that the
CD27–CD70 interaction in HIV infection may provide CD27
 
  
 
CD8
 
  
 
T cells with a survival
advantage and compensate for limiting or absent CD4
 
  
 
T help to maintain the CD8 response.
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Introduction
 
The induction and maintenance of a virus-specific cyto-
toxic CD8
 
  
 
T cell response is sufficient for control of most
chronic viral infections (1, 2), but is not adequate with
HIV. Despite a numerically large HIV-specific CD8
 
  
 
T
cell response during much of the chronic phase of infec-
tion, viral replication persists (3–5) and ultimately infec-
tion progresses to AIDS (6–9). The failure of CD8
 
  
 
cells
to contain HIV reflects evasion by the virus, resulting in
part from the high mutation rate and down-regulation of
class I antigen expression in infected cells (10–12), as well
as preferential depletion of the HIV-specific CD4
 
  
 
T
helper cell response, which is likely essential as demon-
strated in other chronic viral infections to maintain an ef-
fective CD8
 
  
 
response (13–16). Analysis of the responding
CD8
 
  
 
T cells (4, 17–19) has also suggested that abnormal-
ities in function and differentiation of HIV-specific CD8
 
 
 
T cells may contribute to inadequate control. HIV-specific
CD8
 
  
 
T cells isolated from peripheral blood of infected
individuals do not directly ex vivo efficiently lyse target
cells. The impaired cytolytic activity, which can be par-
tially restored by exposure to exogenous IL-2 (17), is asso-
ciated with decreased expression both of key signaling
molecules such as CD3
 
  
 
and CD28, and of perforin (4,
18–20). The majority of HIV-specific effector cells also
continue to express CD27, and it has been suggested that
such incomplete differentiation of HIV-reactive CD8
 
  
 
T
cells may contribute to the observed functional impair-
ment (4, 20–22).
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A largely linear differentiation pathway of human CD8
 
 
 
T cells from naive cells to memory and effector cells has
been proposed, based in large part on expression of a panel
of cell surface molecules (20, 23, 24). Naive CD8
 
  
 
T cells
are CD45RA
 
 
 
28
 
 
 
27
 
 
 
CCR7
 
  
 
and respond to antigen
stimulation by extensively proliferating, forming a popula-
tion of “central” (central–memory T cells) or early mem-
ory cells that can efficiently localize in lymphoid nodes,
express the CD45RO isoform, express low levels of
granzyme but not perforin, and have high proliferative ca-
pacity but low cytolytic activity. Further stimulation of
central–memory T cells leads to proliferation with both
self-renewal and production of intermediate memory cells
that have lost CCR7 and CD28 expression, and then to
“effector” (effector–memory T cells) or late memory cells
that lose CD27 expression, exhibit a lower proliferative ca-
pacity but high levels of granzyme and perforin, and are
directly cytolytic. These CD45RO
 
 
 
28
 
 
 
27
 
 
 
CCR7
 
  
 
ef-
fector–memory T cells can be further driven by antigen
stimulation to down-regulate CD45RO and reexpress
CD45RA, becoming “terminally differentiated” effector
cells (23, 25). Maturation of murine CD8
 
  
 
T cells in re-
sponse to model infections has revealed mostly similar phe-
notypic changes, with the precise effector functions of the
originating central–memory T cells still controversial (26).
This model has proven generally descriptive of the tempo-
ral evolution of human CD8
 
  
 
responses, although some
phenotypic exceptions have been identified (27). In HIV
infection, however, the pattern appears disrupted. Despite
persistent stimulation with virus, the majority of HIV-spe-
cific CD8
 
  
 
T cells recoverable from peripheral blood have
retained expression of CD27 and are CD45RO
 
 
 
28
 
 
 
27
 
 
 
CCR7
 
 
 
, which has been interpreted as reflecting a failure
to complete the differentiation process (20, 21). The basis
for such a differentiation block, as well as the potential det-
rimental consequences of retained CD27 expression, still
remain to be elucidated.
Although persistent CD27 expression may serve as a
“marker” for impaired effector function of HIV-specific
CTLs, recent analyses have provided evidence that the
CD27–CD70 interaction provides a costimulatory signal to
T cells. CD27 is a member of the TNFR family, and inter-
action with its transmembrane ligand CD70, which is ex-
pressed on activated T and B cells and potentially dendritic
cells (28, 29), induces a costimulatory signal that activates
NF-
 
 
 
B, promotes survival, enhances TCR-mediated pro-
liferative signals, and increases effector function (30–32).
CD70 is overexpressed in HIV-infected patients, and per-
sistent signaling to CD27
 
  
 
HIV-specific effector cells in in-
fected hosts might theoretically lead either to improved T
cell function (30–32) or to T cell dysfunction (32, 33),
probably depending on the amount, duration, and timing
of the CD70 signal provided. An alternative hypothesis for
CD27 expression has been proposed in which differentia-
tion of the responding CD8
 
  
 
population may reflect
unique properties of the particular viral infection (20). For
example, in CMV infection the majority of virus-specific
memory cells are CD27
 
 
 
, whereas in EBV the memory
population contains CD27
 
  
 
cells but is enriched for CD27
 
 
 
cells (20, 34). However, how different viruses could elicit
or select distinct differentiation patterns and the phenotype
of cells actually mediating the effector functions have not
been resolved.
In this work, we have monitored CD27 expression after
cloning and repetitive stimulation of initially CD27
 
  
 
HIV-
specific CD8
 
  
 
T cells, and compared the CD27
 
  
 
and
CD27
 
  
 
subpopulations derived from the same parental
clone. Ligation of surface CD27 by CD70 in association
with a stimulatory TCR signal led to down-regulation of
CD27, which was transient for most cells, but a substantial
fraction of CD27
 
  
 
cells permanently converted to CD27
 
 
 
cells with each successive stimulation. The cells retaining
CD27 expression exhibited normal effector functions com-
pared with the CD27
 
  
 
population. Moreover, the CD27
 
 
 
cells produced IL-2 and exhibited improved survival and a
greater proliferative response in vitro if a CD27 costimula-
tory signal was delivered with the TCR signal. After adop-
tive transfer of a mixed population into an HIV-infected
individual, the CD27
 
  
 
subset, but not the CD27
 
  
 
subset,
derived from the same clone persisted in vivo. The results
suggest that the predominance of CD27
 
  
 
CD8
 
  
 
HIV-reac-
tive T cells in infected individuals may not reflect an ab-
normality in differentiation, but rather an appropriate com-
pensatory event reflecting the survival and proliferative
advantages of such cells after target recognition, particularly
in a CD4-deficient environment, which likely serves to en-
hance and sustain the antiviral response.
 
Materials and Methods
 
Clinical Protocol and Patient Characteristics.
 
Patient number 15249
was a participant in Protocol 1313, which was approved by the
Fred Hutchinson Cancer Research Center Institutional Review
Board, the Food and Drug Administration, and the Recombinant
DNA Advisory Committee. Patient entry criteria included the
following: HIV seropositive by Western blot, no prior history of
opportunistic infections, CD4
 
  
 
T cell count 
 
 
 
200 cells/mm
 
3 
 
at
the time T cell cultures were initiated, and maintenance of a sta-
ble regimen of antiretroviral therapy for at least 4 wk before study
entry. Plasma HIV RNA was determined by quantitative PCR
by the Roche Amplicor RNA PCR assay.
 
Isolation, Expansion, and Characterization of HIV-, EBV-, and
CMV-specific CD8
 
  
 
CTL Clones.
 
HIV gag– and CMV-specific
CD8
 
  
 
CTL clones were isolated and characterized as described
previously (35). PBMCs were stimulated twice with either autol-
ogous UV-inactivated vac/gag-infected adherent cells, CMV-
infected fibroblasts, or dendritic cells pulsed with the HLA-A2–
restricted EBV peptide (GLCTLVAML) from the BMFL1
protein, and responding cells were cloned by plating at 0.3 cells/
well and stimulating with anti-CD3 and IL-2 in the presence of
irradiated lymphoblastoid cell lines (LCLs) as accessory cells.
The antigen specificity and MHC class I restriction of the HIV
gag–specific CTL clones was determined in a standard 5-h chro-
mium release assay using as target cells autologous and partially
class I MHC–matched allogeneic LCLs that were either mock in-
fected, or infected with a vaccinia recombinant virus expressing
either HIV gag or a control CMV protein. Samples were assayed
at an effector–target ratio of 2.5:1. Epitope mapping was per- 
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formed by pulsing autologous LCL target cells with overlapping
20- or 15-mer peptides, and then synthesizing smaller peptides to
define the minimal epitope.
 
FACS Analysis of Antigen Expression, Carboxyfluorescein Diacetate
Succinimidyl Ester (CFSE) Dilution, and Apoptosis.
 
Anti–TCR-
 
 
 
/
 
 
 
-FITC, anti–CD45RA-PE, anti–CD45RO-PE, anti–CD38-PE,
anti–CD69-PE, anti–Ki67-PE, anti–CCR7-PE, anti-CD62L, anti–
Bcl-2–FITC, anti–CD95-PE, anti–CD28-APC, anti–annexin
V–FITC, anti–perforin-PE, anti–granzyme A–PE, anti–CD27-
PE, and anti–CD70-FITC antibodies were from BD Biosciences;
anti–CD3
 
 
 
-FITC antibody was from Santa Cruz Biotechnology,
Inc.; and anti–proliferating cell nuclear antigen antibody was
from DakoCytomation. Permeabilization buffers were from BD
Biosciences. Perforin staining was performed after methanol-fixa-
tion and triton permeabilization. Purified stimulatory anti-CD27
mAb and blocking anti-CD70 mAb were from Immunotech.
Analyses of intracellular and surface staining were performed with
a FACSCalibur (Becton Dickinson) and sorting was performed
with a FACSVantage (Becton Dickinson).
T cells were labeled with CFSE (Sigma-Aldrich) in PBS at a
concentration of 2 
 
  
 
10
 
6 
 
cells/ml for 10 min at 37
 
 
 
C, followed
by blocking with 10% FCS. 30 ng/ml anti-CD3 and 10 mg/ml
anti-CD27 mAb were adhered overnight to 96-well plates and
CFSE-labeled CTL clones were added at 5 
 
  
 
10
 
4 
 
cells/well.
Three wells with identical conditions were pooled on day 7 for
FACS analysis. Similarly, 10 
 
 
 
g anti-CD3 mAb and 10 
 
 
 
g anti-
CD27 were coated to 96-well tissue culture plates overnight.
CD27
 
  
 
and CD27
 
  
 
T cells were incubated in the coated plates
for 16–18 h in the presence or absence of 2.5 
 
 
 
g/ml of soluble
anti-FAS IgM (BD Biosciences).
 
Proliferation Assays.
 
96-well tissue culture plates were coated
with the indicated amounts of anti-CD3 mAb (OKT3) and anti-
CD27 antibody overnight, washed, and 5 
 
  
 
10
 
4 
 
cells were added
to each well. For antigen-specific stimulation, autologous LCLs
were inactivated with 50 ug/ml mitomycin C for 1 h at 37
 
 
 
C,
washed three times, labeled with peptide for 3 h, and plated at 5 
 
 
 
10
 
4 
 
cells/well in 96-well plates. 2 
 
  
 
10
 
5 
 
responder cells were added
in duplicate or triplicate wells and 5 
 
 
 
g/ml anti–IL-2 receptor 
 
 
 
chain mAb (R&D Systems) was added to selected wells. Cultures
were pulsed with 1 
 
 
 
Ci [
 
3
 
H]TdR for the final 18 h of a 90-h assay.
 
Cytokine Production.
 
Cytokine production was assessed after
stimulation as described above with either anti-CD3 mAb/anti-
CD27 mAb stimulation or peptide stimulation. IL-2 production
was determined after 36 h either by ELISA (R&D Systems) or by
FACS using the CBA kit (BD Biosciences). Intracellular IFN-
 
 
 
production was assessed after stimulation of T cells with autolo-
gous peptide-pulsed LCLs for 5 h in the presence of 10 
 
 
 
g/ml
brefeldin A (Sigma-Aldrich). 10 ng/ml PMA- and 1 
 
 
 
g/ml iono-
mycin-treated (both from Sigma-Aldrich) T cells were used as
positive controls.
 
Telomere Length Analysis by Fluorescence In Situ Hybridization and
Flow Cytometry.
 
The average length of telomere repeats in indi-
vidual lymphocytes was measured by automated flow FISH as de-
scribed previously (36). Cells were hybridized with or without
0.3 
 
 
 
g/ml of telomere-specific FITC-conjugated (C
 
3
 
TA
 
2
 
) PNA
probe (provided by Applied Biosystems), washed, and counter-
stained with 0.01 
 
 
 
g/ml LDS 751 (Exciton Chemical Co. Inc.).
To convert the specific fluorescence (fluorescence measured in
cells hybridized with the FITC-labeled telomere PNA probe mi-
nus the autofluorescence of unstained cells) into kilobase telo-
mere length, an internal standard (cow thymocytes) with a
known telomere length was processed and analyzed simulta-
neously with each sample.
 
Quantification of T Cell Clone Frequency In Vivo.
 
T cell recep-
tor variable gene usage was analyzed by multiplex PCR as described
previously (37). Direct DNA sequencing was performed bidirec-
tionally using either the TCR
 
 
 
c primer or the primer for the iden-
tified specific TCRV
 
  
 
with Therma Sequenase (Amersham Bio-
sciences). The resulting sequence was compared with known TCR
sequences using BlastSearch to define the variable region.
A commercially available kit (TaqMan PCR core reagent kit;
Applied Biosystems) was used for PCR mastermixes. The ampli-
fication mix and PCR conditions for a 50-
 
 
 
l reaction consisted
of the following: 1X PCR buffer A; 0.5 U AmpErase (uracil gly-
cosylase); 1.25 U AmpliTaq Gold polymerase; 3.5 mM MgCl
 
2
 
;
200 
 
 
 
M dATP, dGTP, dCTP, and dUTP; 41.5 
 
 
 
mol forward
and reverse primers; and 10 
 
 
 
mol TaqMan probe (Synthegen),
where FAM is 6-carboxy fluorescein (emission: 518 nm) and
TAMRA is 6-carboxy tetramethyl rhodamine (emission: 582
nm). Reaction volumes were adjusted to 50 
 
 
 
l and transferred to
a microtiter plate. The following primer and probes were used
for patient number 15249: ATGTGAGCACCTTGGAGCTG,
TTCAGTCCCCCCCAGACT, and 5
 
 -FAM-CGCAAAGAT-
AAAGGGCCGAGTCCC-TAMRA-3 . The concentration of
the T cell clone in test samples was determined with  -globin
used as an internal standard on an identical set of samples. The
procedure used  -globin–specific primers (TGAAGGCTCATG-
GCAAGAAA and GCTCACTCAGTGTGGCAAAGG) and
fluorogenic probe (5 -FAM-TCCAGGTGAGCCAGGCCAT-
CACTA-TAMRA-3 ). Target and internal control DNA were
subjected to 50 C for 2 min and 95 C for 10 min, followed by 45
cycles of amplification at 95 C for 20 s and 60 C for 1 min, using
ABI PRISM 7700 sequence detector (PerkinElmer). The fre-
quency of transferred T cells per total PBMC was calculated us-
ing the results obtained by the clonotypic PCR divided by the
total number of PBMCs as assessed by the  -globin–specific
PCR in each individual sample. The frequency per CD8  T cells
was calculated from the results of the white blood differential
count and the analysis of T cell subsets. To assess surface expres-
sion of CD27 and annexin V of the transferred T cells, samples
were stained with a fluorescent antibody (BD Biosciences) and
sorted for positive and negative cells on a FACSVantage (Becton
Dickinson). The quantity of transferred cells in positive and neg-
ative populations was assessed using the CDR3-specific quantita-
tive PCR as described above.
Results
CD27 Expression on HIV-, CMV-, and EBV-specific T
Cell Clones. HIV-, CMV-, and EBV-specific CD8  T
cell clones were each independently generated from four
different donors and one to two concurrently derived T
cell clones from each donor were analyzed for CD27 sur-
face expression. CD27 was detectable on all HIV- and
most EBV-specific T cell clones, but not on any CMV-
specific T cell clones (Fig. 1 A). All but one HIV-infected
patient (no. 07966) had virus copy numbers below the de-
tection limit. Surprisingly, CD27 expression on cells from
several of the HIV- and EBV-specific T cell clonal popula-
tions was not uniform, with some cells CD27  and others
CD27 . Although the T cell clones were isolated after
plating at 0.3 cells/well, this phenotypic heterogeneity
raised the possibility that the cell populations might not be
of clonal origin. Therefore, the TCR genes of the two het-CD27 Promotes Long-Term Survival of Effector–Memory CTLs 1410
erogeneous HIV-specific T cell clones were sequenced and
clone-specific primers were designed from within the hy-
pervariable CDR3 region of the T cell receptor. Real-time
PCR on DNA prepared from sorted CD27  and CD27 
subsets demonstrated usage in each instance of a single
identical TCR, confirming that both subsets were derived
from the same T cell (not depicted).
The expression of CD27 on all HIV-, some EBV-, and
no CMV-specific T cell clones is consistent with the re-
ported in vivo phenotypes of polyclonal T cells specific for
these viruses (20). Nevertheless, this result was surprising
because all clones were derived by repetitive stimulation
and extensive proliferation, which has been associated with
telomere shortening and loss of CD27 expression (23).
Therefore, we assessed if the populations with CD27  cells
had undergone fewer cell divisions before and during the
cloning process than the CD27  populations by measuring
with automated flow FISH telomere lengths in individual
lymphocytes (36). The average telomere lengths of HIV-,
EBV-, and CMV-specific T cell clones were comparably
short ( 5 kb), suggesting that independent of retention or
loss of CD27 expression, these populations had all experi-
enced a large number of cell divisions (Fig. 1 B). The T
cells reactive with these viruses were likely all primed by
professional APCs in vivo, but then experienced different
in vivo events as well as disparate initial stimulation condi-
tions in vitro, with CMV-specific T cells stimulated by in-
fected fibroblasts in contrast to professional APCs for HIV
and EBV, all of which may have influenced the resulting
CD27 expression. However, all T cell clones were then
expanded in the presence of LCLs, which express CD70,
and all CD8  cells transiently up-regulated CD70 in re-
sponse to T cell receptor stimulation independent of CD27
expression (Fig. 2 A), suggesting that differences in the
ability of CD27 to be ligated by CD70 during repetitive
stimulations in vitro could not account for the observed
distinct phenotypes of the HIV-, CMV-, and EBV-specific
T cell clones.
Figure 1. CD27 surface ex-
pression and telomere length on
HIV-, CMV-, and EBV-specific
CD8 clones. All HIV-specific
CD8 clones recognized the gag
protein, with two restricted to
the B57 allele, two to B8, and
two to B13. Two independently
generated clones were analyzed
for patient numbers 15249 and
16342. Two CMV-specific T
cell clones were A2 restricted
and pp65 specific, one was specific for the immediate early protein with unknown restriction, and two were specific for unknown CMV proteins. All
EBV-specific CD8 clones were A2-restricted and recognized the BMFL1 peptide. (A) Surface expression of CD8 clones was assessed by FACS, with the
percentage of CD27  cells of total T cells shown. (B) Telomere length of the same clones was analyzed by FACS. Virus copy number in plasma and
CD4  T cell count at the time point cells were obtained for cloning are indicated for HIV-infected patients.
Figure 2. CD27 expression af-
ter T cell activation. Virus-specific
clones were expanded with anti-
CD3 mAb in the presence of
LCLs, irradiated feeder cells, and
IL-2. At the time points indi-
cated, (A) CD27  CMV-specific
clone MT (and pp270, not de-
picted) and (B) CD27   EBV-
specific clone EG 4 (and
RS 26, not depicted) were ana-
lyzed by FACS for CD27 and
CD70 expression. (C) HIV gag–
specific T cell clone 9G6-35
(and 42E5-176, not depicted),
which initially contained both
CD27  and CD27  cells, were
sorted and the fate of the CD27 
and CD27  T cells was separately
analyzed. (B and C) At the end
of a stimulation cycle of initially
CD27  EBV- and HIV-specific
cells, the cells were sorted for
CD27 expression and the CD27  and CD27  cells were monitored through the next cycle. (D) The T cell clones 9G6-35 and 42E5-176 were repeti-
tively expanded, and CD27 expression was assessed 14 d after anti-CD3 mAb stimulation. (E) Telomere lengths of CD27  and CD27  cells at the end of
the fifth in vitro expansion were compared. (F) CD27  T cells from clone 42E5-176 were stimulated by plate-bound anti-CD3 mAb for 4 d in the presence
or absence of 5  g/ml anti-CD70 mAb. Surface expression of CD27 4 d after stimulation is shown.Ochsenbein et al. 1411
The CD27  and CD27  subpopulations from individual
HIV-specific clones were isolated by FACS sorting after a
stimulation cycle, and CD27 and CD70 expression by the
subpopulations was then monitored after restimulation
with anti-CD3 and low dose IL-2 (50 U/ml), and com-
pared with the responses of CD27  CMV-specific and
CD27  EBV-specific clones. Both CD27  and CD27  T
cells transiently up-regulated CD70 expression, and the ini-
tially positive CD27 T cells lost surface CD27 expression
by days 5–9 (Fig. 2, A–C). However, at the end of the 15-d
stimulation cycle, CD70 expression was again low, the ini-
tially negative CD27 cells remained CD27 , and most of
the initially positive CD27 cells reexpressed CD27. A small
fraction of the initially positive CD27 cells failed to reex-
press CD27, and restimulation and analysis of this CD27 
population revealed that this loss was irreversible. Repeti-
tive in vitro expansions of the HIV-specific T cell clones
consisting of CD27  and CD27  subsets led to progressive
loss of CD27  cells with each stimulation and accumulation
of CD27  T cells (Fig. 2 D). The average lengths of telo-
mere repeats in sorted CD27  and CD27  subsets after
completion of the fifth expansion cycle were both short
(Fig. 2 E), again suggesting that both CD27  and CD27  T
cell subsets had extensively proliferated. The transient
down-regulation of CD27 observed after stimulation of
CD27  T cells was dependent on ligation by CD70 be-
cause surface CD27 expression was stable on CD27  cells
after TCR stimulation in the presence of a blocking anti-
CD70 antibody (Fig. 2 D).
The results demonstrate that effector–memory CD27 
CTLs gradually convert to a terminally CD27  phenotype
with successive cell divisions, but that all CD27  cells tran-
siently lose CD27 surface expression after ligation of CD27.
Thus, direct ex vivo analysis of CD27  cells can be poten-
tially confounded by the presence of two very distinct pop-
ulations: recently stimulated CD27  CTLs and terminally
differentiated CD27  CTLs.
CD27  and CD27  HIV gag–specific CD8  T Cells Are
Functionally Distinct. The presence of CD27  and CD27 
cells derived from the same parental T cell clone after ex-
pansion permitted analysis of the function of CD27 on ge-
netically identical HIV-specific T cells. Phenotypically, the
two cell subsets appeared otherwise comparable, with no
differences in levels of TCR chains or CD3  expression, and
both populations were CD45RAlo, CD45ROhi, CD38hi,
CD69hi, Ki67 , proliferating cell nuclear antigenlo, CCR7 ,
CD62L , Bcl-2 , FAShi, and CD28  (not depicted). To fa-
cilitate functional analysis, the fine specificity of the clones
Figure 3. Functional in vitro assays of CD27   and
CD27   CTLs. [3H]thymidine uptake of CD27   and
CD27  cells after sorting and in vitro expansion in response to
(A) autologous LCLs pulsed with the noted concentrations of
peptide, or to (B) titrated amounts of plate-bound anti-CD27
and 30 ng anti-CD3 mAb. (C) [3H]thymidine incorporation
of CD27  and CD27  T cells of the clone 9G6-35 after
three (R3) or six (R6) in vitro expansions in response to
titrated amounts of plate-coated anti-CD3 mAb (OKT3).
Proliferation index was determined as [[3H]thymidine up-
take of stimulated samples]/[[3H]thymidine incorporation
of unstimulated samples]. The [3H]thymidine uptake in
unstimulated CD27  and CD27  subsets was comparable.
(D) The percentage of annexin V   cells is shown in
CD27  and CD27  T cell subsets after stimulation for
16–18 h with 10  g/ml of plate-bound anti-CD3 mAb
and/or 10  g/ml of soluble anti-FAS mAb in the presence or
absence of 10  g/ml of coated anti-CD27mAb. (E) CFSE-
labeled CD27  and CD27  T cells of the clone number
9G6-35 were stimulated with 30 ng/ml of plate-bound
anti-CD3 mAb (OKT3) in the presence or absence of 10
 g/ml of coated anti-CD27 mAb. CFSE expression is
shown 7 d after stimulation. IL-2 production of CD27 
and CD27  cells was assessed after 36 h of stimulation with
(F) peptide-pulsed autologous LCLs or (G) titrated
amounts of plate-bound anti-CD27 and 30 ng anti-CD3
mAb. (H) [3H]thymidine incorporation of CD27  and
CD27  T cells of the clone 9G6-35 was measured after
stimulation with 100 nM of autologous peptide-pulsed
LCLs in the presence or absence of a blocking anti–IL-2R 
mAb. The mean of triplicate samples is shown, with error
bars indicating SEM. All in vitro stimulations presented in
this figure were performed in the absence of IL-2 in the
culture media.CD27 Promotes Long-Term Survival of Effector–Memory CTLs 1412
was determined both by defining the restricting allele with
partially matched targets, and by epitope mapping using
overlapping gag peptides and autologous B cell LCLs as tar-
gets. Clone 9G6-35 from patient number 15249 was B57
restricted and recognized the peptide TSTLQEQIGW.
Clone 42E5-176 from patient number 07966 was B13 re-
stricted and recognized the peptide ERQANFLGKI.
The response of these HIV gag–specific CD8  T cell
clones was assessed after stimulation with autologous pep-
tide-pulsed B-LCLs to mimic recognition of a target cell,
and after stimulation with anti-CD3 and anti-CD27 to di-
rectly analyze the role of CD27 in the absence of other co-
stimulatory signals. The proliferation index of CD27  cells
was twofold higher than CD27  cells after stimulation with
peptide-pulsed autologous LCLs (Fig. 3 A). After stimula-
tion with 30 ng of plate-bound anti-CD3, anti-CD27 had
no effect on the proliferative response of CD27  cells, but,
for CD27  cells, proliferation was directly proportional to
the level of CD27 ligation, with 10  g anti-CD27 increas-
ing [3H]thymidine incorporation up to 100-fold in CD27 
cells compared with CD27  cells (Fig. 3 B). Differences in
[3H]thymidine incorporation between CD27  and CD27 
HIV-specific T cells were more pronounced after six cycles
than three cycles of expansion (Fig. 3 C), suggesting that
the CD27–CD70 interaction may become increasingly im-
portant for CD8  responses as the CD8  cells acquire a
greater proliferative history.
Higher [3H]thymidine incorporation by a cell population
may reflect increased cell division after CD27 signaling
and/or enhanced cell survival. The susceptibility of CD27 
and CD27  T cells with the same TCR to activation-
induced cell death and to FAS-induced apoptosis was ex-
amined at 15–18 d after the last stimulation by sorting
CD27  and CD27  subsets and incubating for 16 h in the
presence of plate-bound anti-CD3 or soluble anti-FAS
(Fig. 3 D). Concurrent signaling via CD27 reduced apop-
tosis induced by TCR triggering with anti-CD3 as well as
apoptosis induced directly by anti-FAS. Proliferation of
CD27  and CD27  T cells in response to anti-CD3 was
analyzed by examining dye dilution in cells labeled with
CFSE. Ligation of CD27 with anti-CD27 increased CFSE
dilution after TCR stimulation (Fig. 3 E). An increased
number of CD27  T cells divided compared with CD27 
T cells, even in the absence of anti-CD27 antibody, poten-
tially due to ligation of CD27 by the CD70 up-regulated
on the surface of the T cells after activation (Fig. 2 A).
CD27 ligation by coated antibody also increased, to a more
limited extent, cell cycling of sorted CD27  T cells (Fig. 3
E), which likely reflects the presence of a small number of
contaminating CD27  cells and/or cells from the sorted
CD27  that had only transiently down-regulated CD27 in
the previous stimulation cycle.
IL-2 is an important growth and survival factor, which is
classically produced after ligation of the TCR and costimu-
latory molecule CD28. However, other costimulatory sig-
nals can promote IL-2 production, and we examined if the
observed differences in proliferation of CD27  and CD27 
T cells might in part reflect IL-2 production (30, 31). HIV
gag–specific CD8  effector–memory T cells were stimu-
lated by antigen (Fig. 3 F) or by titrating doses of anti-CD3
and anti-CD27 (Fig. 3 G). Only the CD27  subset pro-
duced detectable amounts of IL-2, and IL-2 production in-
creased with stronger CD27-mediated signaling. Prolifera-
tion of CD27  cells, and to a lesser extent CD27  CD8  T
cells, was diminished by the addition of a blocking anti-
body to the anti–IL-2R  chain (Fig. 3 H). The observed
incomplete blockade may reflect limitations of this anti-
body and/or contributions of IL-2–independent prolifera-
tive mechanisms. The limited reduction in proliferation of
CD27  cells by antibody to IL-2R  despite failure to
detect IL-2 in the culture supernatant may reflect con-
sumption of low levels of IL-2 by proliferating cells or a non-
specific background effect of the antibody. Thus, although
IL-2 production is not absolutely dependent on ligation of
CD27, the CD27–CD70 interaction quantitatively increases
IL-2 production.
Similar In Vitro Effector Functions of CD27  and CD27 
HIV gag–specific T Cells. The persistence of CD27 expres-
sion on HIV-specific CD8  T cells has been correlated
with impaired effector function and deficient perforin ex-
pression (4, 19). However, intracellular staining and FACS
analysis of CD27  and CD27  subsets of the HIV gag–spe-
cific T cell clones 42E5-176 and 9G6-35 revealed compa-
rable levels of perforin and granzyme A (Fig. 4, A and B).
After stimulation with titrating amounts of peptide pre-
sented on autologous CD70  LCLs, CD27  and CD27 
cells responded equivalently with IFN-  production (Fig. 4
C) and lysed peptide-pulsed target cells with the same effi-
ciency (Fig. 4 D). Although this seems to contrast with the
Figure 4. Effector function of CD27  and CD27  CTLs. Perforin (A)
and granzyme A (B) expression of CD27  and CD27  cells was examined
after sorting and in vitro expansion. An isotype control mAb was included
for comparison. (C) Intracellular IFN-  staining of CD27  and CD27 
subsets from the clone 9G6-35 was evaluated after in vitro stimulation with
LCLs pulsed with different peptide concentrations. (D) Standard 51Cr-
release assay using CD27  and CD27  effector cells of the clone 9G6-35
and 1  M of peptide-pulsed autologous target cells at the effector–target
ratios is indicated. One representative assay out of three is shown.Ochsenbein et al. 1413
reported differences in IFN-  production and lytic activity
of CD27  and CD27  HIV-specific T cells analyzed di-
rectly ex vivo (17, 19, 21), in our experiments the cells
were known to be stimulated and maintained identically,
which cannot be controlled with cells of different pheno-
type obtained directly from an in vivo environment, partic-
ularly with variable viral burdens. Thus, retained CD27
expression is not intrinsically associated with impaired ef-
fector functions or failure to acquire such functions. In
addition, as shown above, the direct ex vivo analysis of
CD27   effector–memory T cells may include recently
stimulated CD27  (transiently CD27 ) T cells that there-
fore express high perforin and IFN-  levels with direct ex
vivo cytolytic activity.
Long-Term Survival of Adoptively Transferred CD27 , But
Not CD27 , HIV gag–specific CD8  T Cells In Vivo. Our
studies demonstrated that CD27  HIV-specific T cells pro-
duce IL-2 after ligation of CD27, are more resistant to
apoptosis, and proliferate better in response to antigen than
CD27  cells with the same TCR derived from the same
parental T cell. Analyzing the potential in vivo relevance of
these observations in humans is difficult. However, we
were able to take advantage of a patient previously entered
on a protocol to evaluate augmentation of HIV immunity
by adoptive transfer of autologous HIV-specific CD8 
clones expanded to large numbers in vitro, because this pa-
tient was treated with a single clone that in retrospect con-
tained a mixture of 64% CD27  and 36% CD27  cells (Fig.
5). Patient number 15249 was receiving anti-retroviral
therapy at study entry with a plasma RNA level of  50
copies/ml, but HIV-RNA was regularly detectable in rest-
ing peripheral CD4  T cells (not depicted). The patient re-
ceived an infusion of 3.3   109 cells/m2 of the autologous
in vitro–expanded HIV gag–specific T cell clone on day 0,
followed by a low dose of IL-2 (2.5   105 U/m2) injected
subcutaneously daily for 14 d to improve the engraftment
of the adoptively transferred cells (38). As previously de-
scribed, the clone administered, 9G6-35, contained both
CD27  and CD27  subsets that did not differ in respect to
effector function or expression of activation or homing
molecules, and had telomeres of equivalent length. The
persistence of each subset was monitored after transfer by
quantitative PCR of separated CD27  and CD27  PBMCs
for the clone-specific CDR3 region. Parental cells from
which the clone was derived could not be detected by
PCR in PBMCs before the cell infusion, but 1 h after the
infusion the transferred cells represented 6% of all CD8  T
cells (Fig. 5). The transferred cells expanded to a maximum
of 10% of all CD8  T cells at 4 d after the infusion, de-
clined in frequency over the next 40 d, and then stabilized
at  2% of all CD8  T cells. At each time point, PBMCs
were sorted for CD8  CD27  and CD8  CD27  T cells,
and the number of infused T cells in each fraction was as-
sessed by quantitative PCR. At the peak of the expansion
of the transferred cells, which represented nearly 10% of
total circulating CD8  cells, the fraction of CD27  cells
had increased (60%), which might reflect transient down-
regulation of CD27 in responding CD27  cells and/or
preferential early expansion of CD27  cells in the presence
of exogenous IL-2. After the peak, the percentage of
CD27  cells continuously declined (29% at day 28 and 8%
at day 42), and this predominantly CD27  population re-
mained engrafted long-term at 104 d. Although we cannot
formally exclude that CD27  HIV-specific CTLs reexpress
CD27 in vivo, such a change was never evidenced during
in vitro analyses, and our results strongly suggest that in-
fused CD27  CTLs preferentially survived in this HIV-
infected patient. Thus, HIV-specific CD8  cells expressing
CD27 appeared to have a survival advantage in vivo, and
the transfer of CD27  cells may permit establishment of a
strong persistent response in HIV  patients.
Discussion
The TNFR family member CD27 is expressed by naive
human CD8  T cells and has been reported to be lost during
clonal expansion and normal differentiation to an effector
cell. Thus, the CD27  CD8  population appears to evolve
Figure 5. Frequency and phenotype of
HIV gag–specific CD8  T cell clones after
adoptive transfer. Autologous 3.3   109/m2
clonal CD8  T cells were infused on day 0
(clone 9G6-35 from patient no. 15249) fol-
lowed by a low dose of IL-2 (2.5   105
U/m2) injected subcutaneously daily for 14 d.
The frequency of the transferred T cells was
followed by quantitative PCR specific for
the CDR3 region as described in Materials
and Methods. At the time points indicated,
CD8  PBMCs were sorted for surface ex-
pression of CD27 followed by quantitative
clonotypic PCR of the sorted samples. The
numbers in the FACS dot plots indicate the
percentage of CD8  T cells, and the num-
bers given as percent PCR product indicate
the percentage of the transferred T cell clone
in the CD27  or CD27  subpopulation.CD27 Promotes Long-Term Survival of Effector–Memory CTLs 1414
from continued stimulation of CD27  precursors and pre-
sumably represents a more differentiated antigen-experi-
enced cell with a more extensive proliferative history and
more complete effector functions than CD27  CD8  cells
(24). However, CD27 expression by virus-specific CD8  T
cells that persist after infection with different viruses has ap-
peared more varied than predicted by such an ordered linear
differentiation schema, despite no clear biological basis for
such differences (4, 20, 34, 39). In this work, we have exam-
ined the nature of the relationship between CD27 expres-
sion and CD8  T cell differentiation and function by di-
rectly comparing in vitro and in vivo CD27  and CD27 
cells derived from the same parental cell, and the results sug-
gest that the current model requires modification.
Panels of clones were independently derived for this
analysis from 12 individuals infected with HIV, CMV,
and/or EBV. Despite the extensive in vitro proliferation
required for cloning, the phenotypes of the clones were
typical of freshly isolated CD8  T cells reactive with these
viruses. In particular, most HIV-specific clones were CD27 ,
a fraction of EBV-specific clones were CD27 , and all
CMV-specific clones were CD27 . Analysis of the HIV-
and EBV-specific CD8  clones derived from single pro-
genitor cells surprisingly also revealed heterogeneity in sev-
eral “clones” with regard to CD27 expression, potentially
mimicking the progression expected of an in vivo response.
Sorting of the CD27  population followed by restimula-
tion revealed that most of these cells had irreversibly lost
CD27 expression. By contrast, dynamic changes were evi-
dent with the sorted CD27  population, with all the cells
down-regulating expression of CD27 shortly after stimula-
tion and the majority reexpressing CD27 at the end of the
proliferative cycle (transiently CD27  CTLs), but a small
fraction converting to stably CD27 . With repeated stimu-
lations of CD27  cells, the fraction of stably CD27  cells
progressively increased. The telomere lengths we measured
in the CD27  and CD27  progeny of a proliferating HIV-
specific CD27  parental clone suggested both populations
had experienced extensive proliferation. These results con-
firm and extend earlier studies demonstrating that poly-
clonal PBMCs irreversibly lose CD27 expression after mul-
tiple in vitro stimulations and that the telomere lengths of
RA  CD27  effector cells and RA  CD27  memory cells
measured directly ex vivo are comparable, but 1–3 kb
shorter than those of naive RA  CD27  cells (23). Taken
together, this suggests that CD27  and CD27  antigen-
experienced CD8  T cells have a comparable proliferative
history. Analysis of telomere length in HIV-specific CD8 
T cells obtained directly from PBMCs has also demon-
strated that expression of CD27 does not necessarily imply
limited prior proliferation (40–42).
With the propensity of CD27  cells to yield with con-
tinued proliferation to CD27  cells, the presence of pre-
dominantly CD27  cells in vivo in the response to some
chronic viral infections suggests that such cells may have a
selective advantage in those particular settings. Signals de-
livered through CD27 could potentially provide a selective
advantage by enhancing proliferation and survival (30, 31,
43). Our finding that both CD27  and CD27  CD8  T
cells were present within the same HIV-specific “clonal”
populations made it possible to directly assess the functional
consequences of retention or loss of CD27 expression.
CD27  cells proliferated better in response to antigen or
direct TCR triggering, with the increased proliferation de-
pendent on ligation of CD27. The increased proliferative
response reflected both a decrease in apoptosis, likely re-
flecting prosurvival signals delivered via NF- B activation
by CD27 (44, 45), and the production of IL-2 as a result of
a costimulatory signal from CD27. The presence of such
signals emanating from CD27 might be particularly helpful
for promoting the survival and persistence of HIV-specific
CD8  T cells for several reasons. First, HIV-specific effec-
tor–memory cells isolated from PBMCs have generally lost
expression of CD28, which might otherwise provide an al-
ternative and more potent costimulatory signal for IL-2
production (46). Indeed, we have recently shown that
enforced reexpression of CD28 in HIV-specific CD28 
CD8  effector T cells by genetic modification restores this
costimulatory signal and IL-2 production (47), but such re-
expression does not naturally occur in CD28  CD8  T
cells. Second, the CD4  response to HIV is generally lost
early in infection, eliminating a usual source of IL-2 for
supporting CD8  responses to viruses (13, 48). Third, the
proapoptotic environment observed for CD8   cells in
HIV-infected individuals likely increases the importance of
delivery of prosurvival signals to T cells (49). Finally, HIV-
specific CD8  T cells exist in a milieu rich in cells express-
ing CD70, including activated T, B, and dendritic cells
(50). Thus, what emerges in HIV infection is a setting in
which the subset of HIV-specific CD8  T cells that retain
CD27 expression might be afforded a strong in vivo selec-
tive advantage, and may help explain how a robust CD8 
response can persist in infected individuals despite the ab-
sence of adequate CD4 help.
One potential caveat with this model as beneficial for the
anti-HIV response is the proposed relationship between loss
of CD27 expression and acquisition of effector function by
CD8  cells (4, 20, 21), which would render the retention of
CD27  cells of limited value to the host. However, our in
vitro analysis of the function of CD27  and CD27  cells de-
rived from the same clonal population suggests that acquisi-
tion of effector function is not intimately linked with loss of
CD27 expression. CD27  cells expressed similar levels of
perforin and granzyme as CD27  cells, produced equivalent
levels of IFN- , and demonstrated identical cytolytic activ-
ity. How may these differences to the reported impaired ef-
fector function of CD27  CTLs be explained? First, direct
ex vivo analysis of CD27  cells from infected individuals
will include recently stimulated CD27  CTLs that are only
transiently CD27 . Due to the recent TCR stimulation,
such cells might be expected to exhibit full effector func-
tions. Second, the functional abnormalities observed in
freshly isolated HIV-specific CD27  CD8  may reflect con-
sequences of the in vivo environment of an HIV-infectedOchsenbein et al. 1415
host, such as limiting T help in the context of a high antigen
burden rather than aberrant differentiation, as supported by
the observed acquisition of IFN-  production and cytolytic
activity after overnight culture in IL-2 (17). Thus, the in
vitro results may reflect the effector potential of CD27  cells
if properly stimulated.
A model in which persistent CD27 expression in HIV-
specific CD8  T cells reflects selection due to a survival ad-
vantage rather than representing a differentiation defect is
also consistent with the phenotypes observed in other in-
fections. The dominant virus-specific memory CD8  pop-
ulation is CD27  in chronic CMV infection, a setting in
which a strong CD4  response that can provide IL-2 is
present and in which the targets such as infected fibroblasts
are CD70  and would not provide CD27  cells with a se-
lective advantage. An intermediate phenotype with both
CD27  and CD27  cells present is observed in EBV infec-
tion, a setting in which the CD4  response can support the
CD27  population that evolves with CD8 proliferation,
but the presence of CD70 on some infected targets such as
B cells can impart an advantage to CD27  cells. Moreover,
in HIV-infected individuals who develop EBV-related
lymphoma, a loss of EBV-specific CD27  CD8  cells and
an accumulation of CD27  CD8  cells has been observed
(21). Although these changes have been interpreted, be-
cause these lymphomas are not well-controlled, as provid-
ing further evidence that abnormal differentiation of the
CD8  response is permissive for EBV disease, the lympho-
mas typically occur late in the course of HIV infection. An
alternative explanation suggested by our data is that the
malignant expansion of CD70  B cells and global loss of
CD4  T helper responses with progressive HIV infection
result, respectively, in preferential selection of the CD27 
population and loss of the helper-dependent CD27  popu-
lation, even though this may still eventuate in a quantita-
tively inadequate response.
Ultimately, in vivo studies are necessary to resolve these
issues, but such studies are difficult to perform in humans.
Recent data from influenza infection of CD27-deficient
mice revealed that the CD27–CD70 interaction mediates a
prosurvival signal essential for maintaining the CD8 re-
sponse at the site of infection, with the contribution of
CD27 signals in proliferation unclear because the mice had
an intact CD4 response (45). Our analysis of CD27 expres-
sion on transferred T cells from a patient in a clinical trial
that we had performed examining adoptive transfer of au-
tologous, in vitro–expanded HIV-specific CD8  T cells as a
means to augment virus-specific immunity in infected indi-
viduals (35) has provided evidence supporting a positive role
for CD27 signals in maintaining the human CD8 response.
After the patient received a clonal HIV-specific CD8  pop-
ulation consisting of both CD27  and CD27  subclones,
cells of both phenotypes could be detected shortly after
transfer, but the fraction of CD27  cells in the persisting
transferred cells began declining shortly thereafter, becom-
ing largely undetectable by day 42 despite the persistence of
large numbers of CD27  cells. At the time of infusion after
in vitro expansion, both CD27  and CD27  cell subsets
were CCR7  and CD62L , suggesting that the detection
of predominantly CD27  cells over time in PBMCs did not
reflect differential homing of CD27  cells to secondary lym-
phoid organs. The observed survival advantage of the trans-
ferred HIV-specific CD27  subpopulation of CD8  cells af-
ter infusion into an HIV-infected host mimics what we
would predict for an endogenous response. Although future
studies might be able to indirectly address this issue in hu-
mans in vivo by monitoring the phenotypic and functional
evolution of virus-specific CD8   responses during the
course of viral infections, the unique opportunity to directly
compare HIV-specific CD27  and CD27  progeny of the
same cell both in vitro and in vivo in this work strongly
supports the hypothesis that the accumulation of CD27  ef-
fector–memory cells in certain chronic viral infections re-
flects a functional adaptive response by the host rather than a
reflection of aberrant differentiation.
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